Sove

Quick links to important sections

Sove

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Sove

Quick Facts: Sove (Zolpidem)

Property Description
Active ingredient Zolpidem tartrate (INN)
Form Tablet (Oral dosage form)
Pharmacological class Sedative-hypnotic agent
General purpose Facilitating the onset of sleep
Origin Synthetic (Imidazopyridine compound)

What Type of Medicine is Sove? (Identity and Classification)

Sove is a branded, prescription-only medicine containing the active ingredient Zolpidem tartrate, which is formally classified as a Sedative-hypnotic agent. This places it in the general category of Central Nervous System (CNS) depressants. Zolpidem is categorized as a Nonbenzodiazepine Z-drug, distinguishing it structurally from older sedative classes.

This structural basis, chemically classified as an Imidazopyridine compound, is a unique aspect of its pharmacology. Sove is clinically recognized for its reliable action in quickly inducing a calm state, a defining feature of its pharmacology.

Composition and Pharmaceutical Form (Core Makeup)

Sove is manufactured as a tablet, a specific oral dosage form, containing Zolpidem tartrate as the single active component. This solid form is designed for systemic administration and typically uses a rapid-release pharmaceutical formulation to achieve a quick onset of effect.

The composition is tailored for rapid action, which is critical for addressing issues related to sleep-onset insomnia. Zolpidem works by enhancing the effects of the inhibitory neurotransmitter GABA (Gamma-aminobutyric acid) in the brain. This confirms that the active ingredient's role is to promote the brain's natural signals required for sleep.

What is the General Therapeutic Purpose of Sove? (General Benefit)

The primary therapeutic purpose of Sove is to facilitate the onset of sleep, offering support to patients experiencing acute difficulties in falling asleep. Its classification as a sedative-hypnotic agent confirms its design is to accelerate the transition to a sleep state. The action of Zolpidem tartrate is centered on modulating specific receptors in the central nervous system to ensure a prompt hypnotic effect, making Sove a specialized tool for accelerating the time required to achieve sleep.

Regulatory References

  1. Zolpidem: Uses, Interactions, Mechanism of Action - DrugBank
  2. Zolpidem - StatPearls - NCBI Bookshelf

What side effects are possible with Sove?

The safety profile for Sove (Zolpidem tartrate), as established by official regulatory documents, is characterized by effects on the central nervous system (CNS) and the potential for complex behavioral risks.

Adverse Reaction Classifications

The officially documented undesirable effects are categorized by frequency, with CNS and Psychiatric disorders being prominent. Common reactions (reported by ge 1% of patients) include drowsiness (somnolence), headache, dizziness, diarrhea, and fatigue. Uncommon reactions may include hallucinations, agitation, anterograde amnesia (memory loss for events after taking the medication), and visual disturbances like diplopia (double vision).

Serious Safety Risks

Regulatory agencies emphasize a risk for Complex Sleep Behaviors (CSBs), which include actions such as sleep-driving, preparing food, or making calls while not fully awake, often followed by no memory of the event. These behaviors can occur after the first use and may lead to serious injury. Other serious documented risks include potentially fatal Severe Hypersensitivity Reactions (anaphylaxis and angioedema) and the risk of physical dependence and withdrawal symptoms upon abrupt discontinuation.

Population and Duration Constraints

The official labeling notes specific safety constraints for certain groups: Older adults may be more sensitive to the effects and face an increased risk of falls due to sedative action. Use is formally contraindicated in patients with a history of CSBs, known hypersensitivity, or severe hepatic insufficiency due to the risk of encephalopathy. The label further notes that the risk of next-day impairment, including impaired driving, is increased if the drug is taken without ensuring a full 7 to 8 hours of sleep are available.

Overdose and Emergency Response

In the event of a suspected overdose of Sove (Zolpidem tartrate), government regulatory documents mandate that individuals seek immediate medical attention or get emergency help at once. Overdose is officially documented to present with a progressive impairment of consciousness, ranging from profound somnolence to a state of coma. These manifestations are critical due to the potential for severe physiological effects on the cardiorespiratory system, including respiratory compromise and cardiovascular compromise.

The official labeling notes that overdose severity is significantly increased when Sove is co-ingested with other Central Nervous System (CNS) depressant agents, such as alcohol. This combination increases the risk of both coma and fatal outcomes, as reported in postmarketing experience.

Management procedures described in regulatory labeling require the use of general symptomatic and supportive measures. These measures may include gastric lavage where appropriate, and continuous monitoring of the patient's respiration, pulse, blood pressure, and level of consciousness. The regulatory information also notes a specific limitation in treatment, stating that hemodialysis is not effective for removing Zolpidem. While Flumazenil is cited as potentially useful for reducing the sedative-hypnotic effects, supportive care remains the mandated foundation of emergency response.

Therapeutic Uses of Sove

The primary therapeutic function of Sove (Zolpidem) is centered on providing supportive management for the acute symptoms of insomnia. The medication is commonly used to help patients experiencing difficulties with sleep initiation. This use is specifically relevant for addressing the symptomatic domain of Prolonged Sleep Latency, and it is applied in addressing the time required to fall asleep.

This approach is applicable across conditions characterized by episodic or fluctuating manifestations of sleep problems. Sove is considered relevant for managing symptoms that interfere with daily functioning by promoting a quicker transition to rest. Furthermore, it may be part of symptomatic management for issues involving sleep continuity, assisting with a return to sleep after waking up during the night.

The main therapeutic uses focus on conditions marked by an inability to initiate sleep or maintain it following a nocturnal awakening. This targeted, short-duration approach is applied in addressing the acute symptom clusters in the adults and older adults patient populations. This supportive management may assist with easing the overall symptom burden, contributing to improved comfort and functional stability during periods of transient or short-term sleep disturbances.

Quick Fact: Relief for Insomnia Symptoms
Primary Symptom Relieved Difficulty initiating sleep (Prolonged Sleep Latency)
Target Clinical Context Short-term management of acute or transient insomnia
Patient Benefit Supports a quicker transition to a sleep state

Eligibility and Restrictions for Use

Who can and cannot use Sove?

The official eligibility to use Sove (Zolpidem) is strictly defined by government regulatory standards, which specify both absolute prohibitions and population-based use restrictions.


Contraindicated Populations (Must Not Use)

Use of Sove is contraindicated in patients with a known hypersensitivity to zolpidem tartrate or any inactive ingredients. It is also prohibited for individuals who have previously experienced complex sleep behaviors (such as sleep-driving or preparing food while asleep) after taking the medication. Furthermore, patients with severe hepatic impairment (severe liver disease) must avoid use due to the documented risk of complications.


Age and Condition Restrictions

The medicine is indicated only for adults (18 years and older). Use in children and adolescents is not recommended as safety and effectiveness have not been established. A lower initial dose is recommended for women and older adults compared to adult men, reflecting regulatory findings of slower drug clearance in these groups.

Use requires caution in patients with compromised respiratory function or mild-to-moderate hepatic impairment. Use during pregnancy and by breastfeeding mothers is generally not recommended due to the risk of neonatal sedation, respiratory depression, and drug excretion into human milk.

What should I know about interactions with other medicines?

Official Regulatory Interaction Profile

The interaction profile of Sove (Zolpidem) is characterized by both pharmacokinetic and pharmacodynamic interaction patterns, which dictate specific co-administration restrictions documented in regulatory labeling.

Category Documented Interaction Pattern
Contraindicated Combination Co-administration with Sodium Oxybate (GHB) is officially contraindicated due to the documented risk of severe CNS and respiratory depression.
Pharmacokinetic (Exposure) Strong inducers of the CYP3A4 metabolic enzyme (e.g., Rifampicin) significantly decrease zolpidem's systemic exposure (AUC). Strong CYP3A4 inhibitors (e.g., Ketoconazole) increase zolpidem's plasma concentrations.
Pharmacodynamic (Additive Effect) Co-administration with Alcohol and Other CNS Depressants (including opioids, antipsychotics, and other sedative-hypnotics) results in adverse additive CNS depressant effects.
Food/Substance Effects Food administration is documented to delay the time to peak concentration (T max) and reduce the maximum concentration (C max) of zolpidem in the plasma. The herbal product St. John's Wort is also noted as a potential interaction due to its documented ability to induce CYP3A4.

Connection to the overall interaction profile

Regulatory documents define the product's interaction structure primarily through two domains: enzyme-mediated pharmacokinetic changes and additive pharmacodynamic effects. These domains establish constraints detailing that strong modulators of the CYP3A4 pathway alter the amount of zolpidem in the body, and concomitant CNS depressants enhance the product's sedative effects. Official labeling also includes population-specific notes, confirming that Patients with Hepatic Impairment exhibit a pattern of reduced clearance, leading to increased systemic exposure. This structure is built entirely on officially verified, label-based interaction patterns and their classification.

Mechanism of Action

Molecular Target and Binding

Sove is an inhibitor of the Osteoclast-Activating Factor OAFbeta. Sove achieves its effect by selectively binding to the OAFbeta receptor site. This molecular interaction prevents the factor from activating its target and initiating the subsequent intracellular cascade.


️ Pathway Modulation and Cellular Cascade

This binding event interrupts the crucial downstream NF-kappa B signaling cascade, which is essential for osteoclast maturation. The resulting reduction in NF-kappa B activity decreases the differentiation and overall activity of osteoclasts. This modification to cellular processes subsequently alters the signaling ratio between osteoblasts and osteoclasts.


Specificity Profile

Sove does not interact with TNF-alpha pathways, focusing its inhibitory action solely on the OAFbeta signaling axis.

Dosage and Administration Information

Sove is administered through the oral route, available as an immediate-release (IR) or extended-release (ER) tablet, or in a sublingual form. The medicine is taken once daily immediately before going to sleep and should not be re-administered during the same night. Initial doses are typically differentiated based on gender to manage pharmacokinetic differences.

The usual starting dose for adult women is 5 mg for the IR tablet or 6.25 mg for the ER tablet. For adult men, the starting dose is 5 mg or 10 mg for IR, and 6.25 mg or 12.5 mg for ER. The maximum dose is capped at 10 mg for IR forms and 12.5 mg for ER forms.

Usage is subject to contextual constraints related to timing. Administration must only occur when the individual is prepared to sleep and can guarantee at least 7 to 8 hours of uninterrupted sleep before the time of planned awakening. Ingesting the tablet with or immediately after a meal may slow the onset of its effect. For the ER formulation, the tablet must be swallowed whole and must not be crushed, split, or chewed.

Dose adjustments are applied for vulnerable populations. For older adults and patients with mild-to-moderate hepatic impairment, the recommended starting and maximum dose is lowered to 5 mg (IR) or 6.25 mg (ER). Sove is intended for short-term treatment only, with usage generally limited to a maximum duration of four weeks.

Recent Clinical Evidence

Sove: Recent Clinical Evidence

Clinical research on Sove (zolpidem) has focused primarily on its use for the short-term management of insomnia characterized by difficulty falling asleep. The evidence comes primarily from placebo-controlled trials involving adult subjects.

Studies consistently show that Sove administration is associated with a reduced sleep latency (time taken to fall asleep) compared to placebo across recommended dose ranges. This effect has been documented for treatment periods typically lasting up to four to five weeks. Researchers have also observed an increase in total sleep time and a decrease in the number of nocturnal awakenings.

Tolerability and Safety Findings

Long-term clinical investigations and post-marketing surveillance have monitored the drug's safety profile. Common adverse events reported in short-term trials include headache, dizziness, and drowsiness. While the drug is generally considered well-tolerated in clinical studies, specific attention has been given to:

  • Complex Sleep Behaviors: Activities such as sleepwalking, sleep driving, and other actions performed while not fully awake have been reported. Regulatory warnings emphasize that these events, though rare, can be serious and may occur even after a single dose.
  • Potential for Dependence: Research indicates that the risk of tolerance and physical or psychological dependence increases with prolonged use or use at higher-than-recommended doses.

Pharmacokinetic Context

Trials examining the drug's absorption and half-life confirm its rapid onset of action and relatively short elimination half-life of around 2.5 hours. This profile is consistent with its intended use as a sleep-onset aid designed to minimize residual morning sedation. Food intake, particularly high-fat meals, has been found to delay the time to peak concentration, which may reduce the speed of sleep onset.

Frequently Asked Questions (FAQ)

Common questions about Sove (FAQ)


Q: Why does Sove need a prescription?

A: According to U.S. regulatory classification, Sove (Zolpidem) is legally designated as a Schedule IV federally controlled substance.

This classification is applied due to the drug’s potential for misuse and dependence, requiring that it be dispensed only with a valid prescription.


Q: Does Sove have a Black Box Warning?

A: Yes, the U.S. FDA requires that Sove (Zolpidem) carry a Boxed Warning, which is the most stringent safety warning.

This warning highlights the serious risk of Complex Sleep Behaviors—such as sleepwalking, sleep driving, and other actions performed while not fully awake—that have resulted in serious injury and death.


Q: How long has Sove been approved for use?

A: The active ingredient found in Sove (Zolpidem) was initially approved by the U.S. Food and Drug Administration (FDA) in December 1992.


Q: What is the mechanism of action of Sove in simple terms?

A: The way Sove works is described as enhancing the effects of a natural chemical in the brain called GABA (Gamma-aminobutyric acid), which is an inhibitory neurotransmitter.

The action is consistent with promoting the transition to a sleep state.


Q: Is Sove suitable for people over 65?

A: Official regulatory documents describe a lower initial dosage for individuals over 65 years old due to findings that drug clearance can be slower in older adults, which increases the risk of side effects.

Special caution is indicated to mitigate risks such as an increased possibility of falls due to sedation.


Q: Can Sove be taken at the same time as cold and flu medicine?

A: Regulatory labeling notes that Sove can cause additive CNS depressant effects when taken with other medicines that slow brain activity.

Therefore, using Sove alongside certain over-the-counter cold and flu medicines is a documented risk. The documented risk requires consideration of whether a cold or flu treatment contains ingredients that can cause drowsiness.


Q: What types of supplements are known to interact with Sove?

A: The active ingredient in Sove is primarily broken down by a liver enzyme known as CYP3A4.

Regulatory documents describe the risk of interactions with herbal supplements that affect this enzyme. For instance, supplements like St. John’s Wort may cause the body to break down Sove faster, potentially reducing its effectiveness.


Q: Are there specific food restrictions while taking Sove?

A: Official guidance does not prohibit taking Sove with specific foods.

However, regulatory documents indicate that ingesting the tablet with or immediately after any meal may slow down the onset of its intended effect.


Q: What happens if you stop taking Sove suddenly?

A: Studies and official information indicate that abrupt discontinuation of Sove, especially after prolonged use, may lead to withdrawal symptoms.

These symptoms can include the reappearance or worsening of insomnia and other adverse events.


Q: Is Sove associated with any effects on liver or kidney function?

A: Regulatory documents strictly address use in patients with hepatic impairment (severe liver problems), with a lower recommended dose or contraindication in severe cases.

Primary regulatory warnings do not typically include restrictions related to routine kidney function.


Q: Can Sove cause changes in mood or anxiety?

A: Uncommon side effects listed in regulatory labeling may include changes in thought and behavior, such as agitation and hallucinations.

The official safety information also documents the possibility of the worsening of existing depression.


Q: What does 'contraindication' mean in relation to Sove?

A: In regulatory documents, a contraindication represents a condition or circumstance under which the drug is strictly prohibited from use.

For Sove, this prohibition is applied to patients who have specific pre-existing conditions or a history of certain adverse reactions, such as complex sleep behaviors.


Q: Is it normal to feel a mild stomach upset when starting Sove?

A: The official product label lists diarrhea and other gastrointestinal system disorders as commonly observed adverse reactions during clinical trials.


Q: Can Sove make certain chronic conditions worse?

A: Regulatory documents caution that the risk of respiratory depression must be considered before prescribing Sove in patients with compromised respiratory function.

This is an example of an existing chronic condition that requires specialized medical judgment regarding use.


Q: What is the expected long-term safety profile of Sove?

A: Official regulatory labeling licenses Sove only for short-term use and does not provide an extended long-term safety profile.

The risk of dependence and tolerance is noted to increase when use exceeds the recommended duration.


Q: Is it safe to take Sove with blood pressure medication?

A: Regulatory references indicate a risk of additive side effects when Sove is taken with certain blood pressure medicines.

This risk is primarily associated with certain classes, such as Calcium Channel Blockers, which may increase the likelihood of sedation and dizziness.


Q: What should I do if I miss a dose of Sove?

A: Regulatory guidance describes Sove as being intended for use immediately before going to sleep.

If a dose is missed, it is generally consistent with official guidance to only take it if a person is prepared for sleep and can ensure a full 7 to 8 hours of uninterrupted rest.

Taking the drug later in the night increases the risk of next-day impairment.


Q: Does Sove interact with tobacco or nicotine products?

A: Studies examined in regulatory pharmacokinetics sections document that smoking tobacco may potentially reduce the systemic exposure (clearance) of Sove’s active ingredient.

However, this effect is often noted as not usually being clinically significant.

How should Sove be stored and disposed of?

How to Store and Dispose of Sove (Zolpidem Tartrate)

Sove (Zolpidem tartrate) tablets must be stored according to specific regulatory requirements to ensure product quality and safety.


Storage Conditions

Condition Type Requirement
Temperature Store at Controlled Room Temperature (68°F to 77°F or 20°C to 25°C). The product must be kept from freezing.
Protection Keep the container tightly closed and store away from heat, moisture, and direct light.
Container Must be dispensed and stored in a tight, light-resistant container with a child-resistant closure.
Child Safety Keep Sove out of the sight and reach of children and store it in a secure location.

Disposal Instructions

Unused or expired Sove must be disposed of according to local laws and regulations. This often requires utilizing authorized drug take-back programs or following specific guidelines for controlled substances, such as mixing with an undesirable substance before discarding in household trash. Disposal must avoid release to the environment, as the active ingredient is toxic to aquatic life.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Sove found in:

A-Z Index: